Cell Therapy Review 2026: Mechanisms, Evidence & the Evolving Landscape
Introduction: Why 2026 Is a Defining Year for Cell Therapy
Cell therapy has grown from a niche experimental discipline into one of the most consequential frontiers in modern medicine. As of 2026, a cumulative total of 10,373 cell therapy clinical trials have been identified worldwide, spread primarily across the United States (3,563 trials), China (3,365 trials), and Europe (1,584 trials). This scale, documented in a February 2026 review in Frontiers in Pharmacology, establishes the global magnitude of a field that now touches oncology, immunology, and regenerative medicine alike.
Most coverage of cell therapy defaults to CAR-T in cancer, and for good reason: it is the most visible success story. The real story in 2026, however, is the full spectrum of modalities, each with distinct mechanisms, evidence bases, and clinical frontiers. This review takes a taxonomy-first approach, mapping the landscape from CAR-T and natural killer cells to mesenchymal and hematopoietic stem cells, and beyond.
Three underreported narratives structure this article: the autoimmune breakthrough expanding cell therapy far beyond oncology; the regulatory evolution reshaping how these products reach patients; and the in vivo paradigm shift that could eliminate the manufacturing complexity holding the field back. Whether the reader is a clinician, researcher, or informed observer, the aim is to synthesize clinical evidence, regulatory intelligence, and emerging science into a single coherent picture.
The commercial momentum is undeniable. The global cell therapy market is estimated at roughly $8.85 billion in 2026 and projected to reach $55.72 billion by 2035, growing at a compound annual rate near 22.69%. That trajectory anchors the field’s importance, even as access and equity remain unresolved.
A Taxonomy of Cell Therapy: Mapping the Full Spectrum of Modalities
A taxonomy-first framework matters because different cell types operate through fundamentally different mechanisms, serve different patient populations, and face different regulatory and manufacturing challenges. Treating “cell therapy” as a monolith obscures the very features that determine clinical success.
Two broad categories dominate clinical research. Immune cell therapies account for 5,167 trials, while stem cell therapies account for 4,796. Oncology represents 56.1% of all research focus areas globally, with immune system diseases at 9.3%. Within the immune cell category, CAR-T therapy is prominent with 2,409 trials; within stem cells, mesenchymal stem cells (1,904 trials) and hematopoietic stem cells (1,550 trials) lead.
The subsections that follow offer a modality-by-modality tour of this landscape.
CAR-T Cell Therapy: The Dominant Force and Its Expanding Frontiers
Chimeric antigen receptor T cells are engineered outside the body to express synthetic receptors that redirect their cytotoxic activity toward tumor-associated antigens, independent of the usual MHC presentation pathway. This engineered specificity is what makes them so powerful against certain cancers.
The approved landscape is now well established. CD19-directed and BCMA-directed CAR-T products have transformed hematologic oncology. BCMA-targeted therapies such as idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have altered the treatment landscape for relapsed or refractory multiple myeloma and have moved into earlier lines of treatment through label expansions.
The CAR-T segment was valued at approximately $5.8 billion in 2025 and is projected to grow from $6.9 billion in 2026 to $22.3 billion by 2033, at a compound annual rate of 18.1%, driven by rising cancer prevalence, personalized medicine adoption, and advances in gene editing.
A central tension shapes the field: autologous versus allogeneic. Autologous products, made from a patient’s own cells, dominate approvals. No allogeneic (off-the-shelf) CAR-T has yet received FDA approval, despite rapid clinical progress. One advantage of allogeneic approaches is speed, with treatment initiation possible within five to seven days of patient identification. The solid tumor challenge and the autoimmune frontier, both closely tied to CAR-T, are examined in depth in later sections.
NK and NKT Cell Therapies: Broad Targeting Without MHC Restriction
Natural killer (NK) cells offer a mechanistic advantage that addresses a key CAR-T limitation. Because NK cells do not rely on MHC-mediated antigen presentation, they can target a broader range of malignancies, including those that escape recognition through antigen loss.
Their safety profile is equally attractive. CAR-NK and CAR-NKT therapies exhibit low immunogenicity and a reduced risk of graft-versus-host disease, making them strong candidates for allogeneic, off-the-shelf products. A notable advance involves generating allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. These cells are being investigated for overcoming resistance in ovarian cancer and other solid tumors that evade standard CAR-T therapy.
These modalities remain largely investigational, but they represent one of the most promising near-term allogeneic platforms.
Mesenchymal Stem Cells (MSCs): Immunomodulation and Tumor-Homing Delivery
Mesenchymal stem cells exert potent immunomodulatory effects. They can activate antitumor effector cells, including T cells, NK cells, and macrophages, and promote normalization of tumor vasculature. Engineered CAR-MSCs take this further by leveraging the natural tumor-homing tropism of MSCs to deliver therapeutic agents directly to tumor sites, including drug-loaded nanoliposomes and oncolytic viruses.
With 1,904 trials, MSCs are among the most active modalities in the stem cell category, reflecting broad interest across oncology, autoimmune, and regenerative applications. Limitations persist, however. The heterogeneity of MSC preparations, variable potency, and the difficulty of standardizing manufacturing remain significant hurdles to consistent clinical performance.
Hematopoietic Stem Cells (HSCs): The Established Foundation
Hematopoietic stem cell transplantation is the longest-established cell therapy modality, and its 1,550 trials reflect a mature but still-evolving evidence base. The mechanism is foundational: HSCs reconstitute the immune system following myeloablative conditioning, enabling treatment of hematologic malignancies, inherited blood disorders, and immune deficiencies.
HSCs also mark one of the most successful convergences of cell and gene therapy to date. HSC-based gene therapy for conditions such as sickle cell disease and beta-thalassemia has delivered durable correction of molecular defects. This established platform connects directly to the induced pluripotent stem cell story explored later in this review.
Regulatory T Cells (Tregs), Dendritic Cells, and Macrophages: Emerging Modalities
Beyond T cells lies a diversifying toolkit. Regulatory T cells (Tregs) play a central role in immune tolerance, giving them therapeutic rationale in autoimmune disease, transplant rejection, and inflammatory conditions. Their clinical development remains early-stage but conceptually compelling.
Dendritic cells function as antigen-presenting cells and have been used in therapeutic cancer vaccines. Commercial success has so far been limited, but mechanistic interest continues.
CAR-macrophages are a newer engineering approach with the potential to penetrate the immunosuppressive tumor microenvironment, a barrier that has stymied solid tumor cell therapy. Together, these three modalities represent the broadening of cell therapy well beyond its T cell origins.
The Solid Tumor Challenge: Progress, Targets, and Strategies
Solid tumors remain the field’s defining unsolved problem. As of July 2025, more than 1,900 active oncology cell therapy trials were ongoing globally, with over half targeting solid tumors. Yet CAR-T has shown lower overall response rates in solid tumors than in hematologic malignancies.
An analysis of 41 clinical trials with results published as of October 2025 identifies both pockets of promise and consistent barriers: antigen heterogeneity, T cell exhaustion, and the immunosuppressive tumor microenvironment. The key tumor-associated antigen targets being pursued include mesothelin (MSLN), GPC-3, B7-H3, Claudin 6/18.2, HER-2, CD70, PSMA, CEA, and EGFRvIII.
To overcome the microenvironment’s immunosuppression, researchers are deploying armored CAR constructs, combinations with checkpoint inhibitors, CAR-macrophage approaches, and agents that remodel the tumor microenvironment. The geographic concentration of this work is striking: 65% of 272 active or completed solid tumor CAR-T trials are based in China, with only 29% in the United States, a competitive dynamic with real implications for global access and intellectual property leadership.
A landmark platform advance arrived in August 2026, when scientists at the Gladstone Institutes and UCSF published in Nature an in vivo genome-wide CRISPR screen that identified genetic edits strengthening CAR-T therapy against solid tumors. The ability to run such screens across the entire genome inside a living animal represents a meaningful leap in how the field engineers better cells.
The Autoimmune Frontier: CAR-T Beyond Oncology
Among the most clinically exciting developments of 2025 and 2026 is the expansion of CD19-directed CAR-T into autoimmune disease. Early clinical studies are demonstrating profound and sustained immune resetting in patients whose conditions were previously treatment-refractory.
The mechanism is elegant: CD19-directed CAR-T depletes autoreactive B cells, potentially resetting the immune system and achieving durable remissions in diseases driven by pathogenic B cell clones. Early studies in lupus, myositis, and systemic sclerosis have shown durable remissions, and a 2026 Nature Medicine report documented outcomes in pediatric patients with treatment-refractory autoimmune diseases.
The autoimmune context differs meaningfully from oncology. Patient populations tend to be younger and often healthier at baseline, the risk-benefit calculus shifts accordingly, and the goal is remission induction rather than tumor eradication. Institutional readiness matters here; a May 2026 roadmap in npj Precision Oncology addresses how centers can prepare for cellular therapies targeting both solid tumors and autoimmune diseases.
Open questions remain, including the durability of remission beyond early follow-up, optimal patient selection, and the long-term immune reconstitution profile. Still, the trajectory suggests cell therapy’s patient population is set to expand dramatically beyond cancer.
iPSC-Derived Platforms and the Off-the-Shelf Promise
Induced pluripotent stem cells (iPSCs) can be differentiated into virtually any cell type at scale, offering a renewable, standardizable source for allogeneic cell therapies. This is a fundamentally different manufacturing paradigm from the individualized, patient-by-patient production of autologous products.
The evidence base is maturing. A 2025 landscape analysis reported 115 regulatory-approved clinical trials testing 83 human pluripotent stem cell products as of December 2024, with more than 1,200 patients dosed and no generalizable safety concerns identified to date. The manufacturing appeal is clear: iPSC-derived therapies can be produced in large batches, quality-tested, and banked, eliminating the individualized manufacturing bottleneck that constrains autologous products.
Challenges remain substantial. Differentiation reproducibility, genomic stability monitoring, the risk of immune rejection, and the complexity of closed-system bioprocessing all demand attention. Hypoimmune engineering approaches are being developed specifically to address immune rejection of donor-derived cells. Limited cellular persistence due to host immune recognition remains the central reason no allogeneic CAR-T has yet reached FDA approval, despite rapid progress.
Alongside CAR-NK and CAR-NKT approaches, iPSC platforms represent the most promising paths to scalable, accessible off-the-shelf cell therapy.
In Vivo Cell Engineering: The Paradigm Shift That Could Redefine the Field
Perhaps the most disruptive near-term development is in vivo CAR-T generation, which reprograms a patient’s T cells directly inside the body, eliminating ex vivo cell processing entirely. Rather than removing cells, editing them in a facility, and reinfusing them, a physician could administer a therapy that engineers T cells in situ.
Several delivery platforms are being explored, each with distinct tropism, payload capacity, and safety profile: lentiviral vectors, adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), and CRISPR-based technologies. This matters because ex vivo manufacturing is the primary driver of the complexity, time, and cost associated with current autologous therapies. In vivo approaches could democratize access, with investor interest having shifted substantially toward in vivo CAR-T as the field’s next major inflection point.
The August 2026 Gladstone and UCSF Nature publication on in vivo CRISPR screens stands as a landmark advance, offering a systematic way to identify edits that improve CAR-T efficacy in solid tumors. Complementing this, a 2026 CRISPRoff/CRISPRon epigenetic programming platform uses an all-RNA approach to program gene expression in primary human T cells without introducing double-strand breaks, offering a safer route for next-generation engineering.
Regulatory and safety unknowns persist. Delivering gene-editing machinery in vivo raises questions about off-target editing, tissue specificity, and long-term genomic stability that regulators will need to address. Investor interest has shifted substantially toward in vivo CAR-T, signaling where the field expects its next major inflection point.
Regulatory Evolution: How the Approval Landscape Is Shifting in 2026
The regulatory foundation is well characterized. The FDA approved 38 cell and gene therapy products through December 31, 2025. Of these, 86.8% carried orphan designation, 92.1% used an expedited approval pathway, and 73.7% were approved based on a single pivotal study. Looking forward, the Center for Biologics Evaluation and Research has approved close to 50 products over the last decade, with 80 or more expected by 2032.
Several 2025 and 2026 reforms are reshaping the pathway. On January 11, 2026, the FDA announced a more flexible approach to Chemistry, Manufacturing, and Controls (CMC) requirements, allowing minor manufacturing changes supported by comparability data and relaxing certain pre-Phase 2/3 manufacturing compliance requirements, a significant operational relief for developers. A May 2026 CMC guidance for biologics license application submissions added further clarity on manufacturing evidence standards.
Two additional pathways deserve attention. The “Plausible Mechanism” approval pathway, introduced in November 2025, is designed for personalized therapies where traditional randomized trial evidence may be impractical; it lowers the evidentiary bar while requiring mechanistic plausibility. A September 2025 draft guidance on innovative clinical trial designs for small populations is directly relevant to rare disease and pediatric cell therapy. An April 2026 guidance on safety assessment of genome editing using next-generation sequencing provides a critical framework for in vivo CRISPR and other editing-based approaches.
In Europe, the new EU Health Technology Assessment framework aims to centralize clinical assessment resources, potentially equalizing pricing and reimbursement decision timelines across member states while preserving each country’s national authority.
Cell Therapy and Regenerative Medicine: A Convergent Frontier
Cell therapy increasingly overlaps with regenerative medicine. Gene and cell therapies now enable targeted modulation of tissue repair programs, replacement of damaged cell populations, and durable correction of molecular defects, expanding the scope of what regeneration can achieve.
Cell-free approaches are gaining traction as a complementary strategy. Conditioned media, secretomes, and extracellular vesicles capture the beneficial paracrine effects of cell therapy while simplifying storage, dosing, and safety management. This shift from cell-based to cell-free precision medicine reflects a maturing understanding of how therapeutic cells deliver benefit.
Xenotransplantation represents a parallel frontier. In 2024, the first transplantation of a gene-edited pig kidney into a living human recipient was reported. In 2025, the FDA cleared initial multi-patient clinical trials of genetically modified pig kidneys, signaling xenotransplantation’s move toward structured clinical evaluation. Cell therapy also intersects with scaffold-based and bioprinted tissue constructs in regenerative applications.
Across all these modalities, shared manufacturing bottlenecks persist: closed-system bioprocessing, differentiation reproducibility, and a structural manufacturing talent gap.
Access, Equity, and the Structural Challenges of Scaling Cell Therapy
The field faces an access crisis that its scientific success cannot resolve on its own. One-time cell and gene therapies now routinely reach price points that challenge traditional reimbursement models designed for chronic, recurring treatments, creating significant affordability and equity concerns. High patient cost-sharing compounds the problem, creating avoidable access barriers. Value-based insurance design approaches that eliminate or reduce patient cost sharing are being proposed and piloted.
Geography adds another layer: CAR-T administration requires specialized facilities, and community oncology settings face barriers including referral pathways, manufacturing timelines, and institutional readiness.
The global imbalance is stark. With solid tumor CAR-T trials concentrated in China and the United States and minimal representation in low- and middle-income countries, a structural inequity governs who benefits from these advances. Policy solutions under discussion include value-based insurance design, CMS Innovation Center models, phased public-private financing frameworks, and outcomes-based contracting that aligns payment with long-term value. The EU HTA framework offers a comparative model for equalizing access across member states. Underlying all of this is a manufacturing talent gap, where the availability of trained personnel represents a genuine bottleneck to scaling the field.
The Competitive Landscape: Key Players and the China-US Dynamic
The market is concentrated. The top 10 players in the cell and gene therapy market account for approximately 67% of total revenue, with Novartis, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, and Sarepta Therapeutics among the leaders.
China is a defining force. Chinese assignees including Legend Biotech, UTC, IASO, and CARsgen represent roughly 30% of the CAR-T competitive landscape, and China accounts for 3,365 of the 10,373 global cell therapy trials, nearly matching the United States. The Chinese pipeline is heavily focused on solid tumors, holding 65% of active or completed solid tumor CAR-T trials, with significant activity across CD19, BCMA, and Claudin18.2 targets.
The acceleration of Chinese-origin approvals and the geographic concentration of solid tumor trial data carry implications for global regulatory harmonization and technology transfer. Rather than a zero-sum contest, the US-China competition functions as a driver of innovation, accelerating the pace of clinical development and manufacturing advances worldwide.
Toxicity Management and Safety: The Evolving Clinical Standard
Safety management has matured alongside efficacy. The primary toxicity concerns with CAR-T therapy are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Standardized CRS and ICANS grading systems, earlier protocol-driven intervention with tocilizumab and corticosteroids, and institutional management algorithms have significantly improved outcomes.
Next-generation construct design aims to raise the therapeutic index. Armored CARs with built-in safety switches, logic-gated constructs requiring dual antigen recognition, and split-receptor designs are all under development. Emerging modalities carry different profiles: CAR-NK and CAR-NKT therapies exhibit reduced graft-versus-host disease risk, while in vivo approaches raise distinct questions around off-target editing and tissue specificity.
Regulators require extended safety monitoring for cell and gene therapy products, reflecting the novelty and durability of these interventions. The CRISPRoff/CRISPRon platform’s safety rationale fits this trend: by avoiding double-strand breaks, it reduces the risk of unintended genomic rearrangements, a key concern with conventional CRISPR editing in T cells.
Conclusion: Synthesizing the 2026 Cell Therapy Landscape
Cell therapy in 2026 is not a single field but a diverse ecosystem of modalities, each with distinct mechanisms, evidence bases, and clinical trajectories, unified by the shared goal of durable, targeted therapeutic intervention.
Three underreported narratives define the moment. First, the autoimmune frontier is expanding the patient population that can benefit from cell therapy well beyond oncology. Second, the FDA’s regulatory evolution is creating more flexible, adaptive pathways that will accelerate approvals. Third, in vivo engineering represents the most disruptive near-term paradigm shift, with the potential to eliminate the ex vivo manufacturing complexity that constrains the field today.
Substantial challenges remain. Access and equity, manufacturing scalability, the solid tumor barrier, and the long-term durability of responses are the defining unsolved problems. With 80 or more cell and gene therapy products expected by 2032 and the market projected to grow at a compound annual rate above 22%, the field is entering a period of accelerating clinical translation. Yet the benefits will only be broadly realized if access, equity, and manufacturing are addressed in parallel.
The convergence of cell therapy, gene editing, regenerative medicine, and regulatory innovation positions 2026 as an inflection point that will help define the therapeutic landscape for the next decade.
Stay Informed: Explore the Latest in Cell Therapy and Regenerative Medicine
The cell therapy landscape is evolving faster than any single report can capture. Adiamed provides ongoing coverage at the intersection of clinical research, regulatory intelligence, and regenerative medicine, tracking new clinical data, regulatory guidances, and platform advances as they emerge.
Readers are invited to explore Adiamed’s broader content on cell therapy, gene editing, regulatory science, and regenerative medicine, and to follow its research coverage for timely, evidence-grounded analysis. In a field where sophisticated synthesis is rare, Adiamed aims to be the point where clinical evidence, regulatory developments, and emerging science converge in one coherent view.
Those who found this review valuable are encouraged to share it with colleagues, engage with related content, or reach out with questions. As the science advances and the regulatory landscape continues to shift, staying informed is the surest way to understand where cell therapy is heading next.
